LD-2 Disclosure Form

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual

NATIONAL MULTIPLE SCLEROSIS SOCIETY

2. Address

Address1

One M Street, SE

Address2

Suite 510

City

WASHINGTON

State

Zip Code

20003

Country

USA

3. Principal place of business (if different than line 2)

City

State

Zip Code

Country

4a. Contact Name		b. Telephone Number	c. E-mail
Ms.	Natasha Silva	7742633027	natasha.silva@nmss.orf

5. Senate ID#

69674-12

7. Client Name	Self	Check if client is a state or local government or instrumentality
NATIONAL MULTIPLE SCLEROSIS SOCIETY

6. House ID#

357890000

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

Supporting the following funding levels in FY24 appropriations bills:
LHHS- $500 million for the Agency for Healthcare Research and Quality, $11.6 billion for the Centers for Disease Control and Prevention (inclusive of $5 million for the National Neurological Conditions Surveillance System), $20 million for the Lifespan Respite Care Program, Robust support for Medicare and Medicaid and protection of Medicaid's current financing structure, $51 billion for the National Institutes of Health, any funding for the Advanced Research Projects Agency for Health should supplement, rather than supplant NIH core investment and at least $15.5 billion for the Social Security Administration.

FDA - $372 million increase in BA (taxpayer) funding, including $3 million to fund the Neurology Drug Program.

MilConVA- support inclusion of report language that includes Neurology Centers of Excellence. - The Committee recognizes the increasing number of Veterans affected by neurologic conditions, including but not limited to: epilepsy, headache, multiple sclerosis, and Parkinsons disease. The Neurology Centers of Excellence provide essential innovative clinical care, education, and research efforts focused on these conditions. The Committee applauds the Department for recent investments into headache, multiple sclerosis, and Parkinsons disease centers and acknowledges the advancement and expansion the Centers have begun. The Committee encourages further investment and collaboration of the Centers across disciplines and directs the Department to allocate at least $72,500,000 for the Neurology Centers of Excellence for maintenance and expansion. Within this total, the Committee recommends the following amounts: $19,000,000 for epilepsy; $30,000,000 for headache; $7,500,000 for multiple sclerosis; and $16,000,000 for Parkinsons disease.

DoD- $22 million for the MS Research Program and increased baseline funding of at least 5% plus inflation for the Congressionally Directed Medical Research Programs.

H.R. 3746- the Fiscal Responsibility Act of 2023- monitor for impact on priority issues. Opposed discussed provision to require Medicaid work requirements.

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH)